Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Global Prevalence of Gynecological Diseases
4.2.2 Rise in Healthcare Awareness along with Increasing Ageing Female Population
4.3 Market Restraints
4.3.1 Stringent Regulatory Framework that Delays the Approval of Products
4.3.2 Expensive Patented Products
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 Therapeutics
5.1.1 Hormonal Therapy
5.1.2 Non-hormonal Therapy
5.2 By Indication
5.2.1 Gynecology Cancers
5.2.2 Menopausal Disorder
5.2.3 Polycystic Ovary Syndrome
5.2.4 Contraception
5.2.5 Others
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Online Pharmacies
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Allergan Plc
6.1.2 Pfizer Inv
6.1.3 AbbVie Inc
6.1.4 TherapeuticsMD Inc
6.1.5 Ferring Holding SA
6.1.6 Lupin Pharmaceuticals Inc
6.1.7 Johnson & Johnson
6.1.8 Eli Lilly and Company
6.1.9 Bayer AG
6.1.10 Allergan Plc


7 MARKET OPPORTUNITIES AND FUTURE TRENDS